Pharma BD Deal Intelligence
Ipsen's $247M Epizyme buy for Tazverik ended in collapse: the SETD2 asset EZM0414 was terminated in 2025, and on March 9, 2026 Ipsen voluntarily withdrew Tazverik worldwide after SYMPHONY-1 flagged secondary hematologic malignancies, capping a franchise that generated just EUR 40.6M.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ipsen is acquiring Epizyme for about $247 million upfront plus a CVR that could add up to $4 per share in deferred milestones, handing the French pharma an…
French drugmaker Ipsen agreed to buy U.S. biotech Epizyme for about $247 million in cash, it said on Monday, adding a rare cancer drug to its portfolio. Under…
Ipsen voluntarily withdrew tazemetostat from all markets following a safety signal in the confirmatory SYMPHONY-1 trial, where the IDMC flagged adverse events…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Ipsen acquired Epizyme for $1.45/share cash (~$247M upfront) plus a non-tradable CVR of up to $4/share, announced June 27, 2022 and closed August 8, 2022. The deal added Tazverik (tazemetostat), a first-in-class FDA-approved EZH2 inhibitor for relapsed/refractory follicular lymphoma and epithelioid sarcoma, plus EZM0414, a Phase 1 SETD2 inhibitor (Fast Track in MM/DLBCL). POST-CLOSE OUTCOME: the thesis did not hold. EZM0414's SET-101 study (NCT05121103) was terminated in 2025 for a 'strategic business decision,' ending the pipeline arm. On March 9, 2026 Ipsen voluntarily withdrew Tazverik in all indications from all markets and discontinued all tazemetostat trials and expanded-access programs, after the confirmatory Phase Ib/III SYMPHONY-1 trial surfaced a safety signal of secondary hematologic malignancies (IDMC: risks may outweigh benefits). With 2025 Tazverik sales of only ~EUR 40.6M (~$47M, -13% YoY), the CVR's $250M sales milestone is effectively unreachable. The acquisition closed as an M&A transaction, but both acquired assets are now off the market or terminated.
15K US cases/yr · $2.2B Global follicular lymphoma therapeutics market 2022 · ~20% Share of FL cases with EZH2 Y641/A677 gain-of-function mutations
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma subtype, accounting for ~22% of U.S. NHL cases with approximately 15,000-17,000 new diagnoses annually. Clinical course is chronic-relapsing, with median overall survival now exceeding 20 years under modern therapy but progression-free survival shortening with each line of therapy. Relapsed/refractory FL after two or more prior regimens (3L+) represents the core label for Tazverik (tazemetostat, EZH2 inhibitor) — the franchise asset Ipsen acquired in the Epizyme deal. EZH2-mutant FL (found in ~20% of FL cases via EZH2 Y641/A677 mutations) responds more robustly to tazemetostat, while wild-type FL retains activity. Commercial dynamics in 3L+ FL are crowded post-2021: CAR-T (Yescarta/axi-cel, Kite/Gilead; Breyanzi/liso-cel, BMS), bispecifics (Columvi/glofitamab, Roche; Epkinly/epcoritamab, Genmab/AbbVie), and PI3K inhibitors (Copiktra/duvelisib, Secura Bio) compete for sequencing slots. Tazverik carries the advantage of oral dosing, manageable safety, and outpatient delivery — the exact profile Ipsen's specialty oncology commercial infrastructure is built to support. 2021 Tazverik net revenue was ~$35M with flat trajectory into 2022, underscoring the modest commercial scale Ipsen acquired at a post-cash-close ~$247M headline price plus CVR.
The 3L+ follicular lymphoma competitive landscape has intensified dramatically since Tazverik's June 2020 accelerated approval. EZH2 inhibition is a Tazverik (tazemetostat, Ipsen/Epizyme) monopoly but challenged by rapidly scaling bispecific CD20xCD3 T-cell engagers — Columvi (glofitamab, Roche) and Epkinly (epcoritamab, Genmab/AbbVie) — which have produced high overall response rates in 3L+ FL and received FDA approvals with convenient outpatient/step-up dosing. CAR-T therapies Yescarta (axicabtagene ciloleucel, Kite/Gilead) with ZUMA-5 FL data and Breyanzi (lisocabtagene maraleucel, BMS) compete in academic centers. PI3K inhibitors Copiktra (duvelisib) and Aliqopa (copanlisib, Bayer) have been largely sidelined by toxicity concerns. Lenalidomide-rituximab (R2, Revlimid/Celgene-BMS + Rituxan) remains a backbone comparator. Tazverik's sequencing niche is community-oncology-deliverable oral monotherapy with manageable safety for patients unsuitable for bispecific/CAR-T referral — a durable but commercially narrow position that shapes Ipsen's ~$247M acquisition math.
NCT05121103, the Phase 1/1b study of SETD2 inhibitor EZM0414 in R/R multiple myeloma and DLBCL, was terminated for a 'strategic business decision' — ending the pipeline arm of the Epizyme acquisition.
Ipsen withdrew Tazverik in all indications (follicular lymphoma, epithelioid sarcoma) from all markets and discontinued all tazemetostat trials/EAPs, after the confirmatory SYMPHONY-1 trial showed a safety signal of secondary hematologic malignancies. The lead asset of the 2022 Epizyme acquisition is off the market.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ipsen S.A. / Epizyme Inc. (this deal) | 2022 | $247M | — |
| Ipsen S.A. / Exelixis Inc. | 2016 | $855M | 80 |
| Ipsen S.A. / Kartos Therapeutics, Inc. | 2026 | $1.8B | 68 |
| Ipsen S.A. / Memo Therapeutics AG | 2026 | $797M | 66 |
| Ipsen S.A. / Clementia Pharmaceuticals Inc. | 2019 | $1.3B | — |
| Ipsen S.A. / Marengo Therapeutics, Inc. | 2024 | $1.2B | — |
| Ipsen S.A. / GENFIT | 2021 | $543M | — |
← Browse all deals · How we score deals
More: 2022 deals · Ipsen S.A. deals · Hematology deals